291 related articles for article (PubMed ID: 31174043)
1. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
4. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
5. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
7. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M;
Mult Scler; 2018 Jun; 24(7):963-973. PubMed ID: 28554238
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
9. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Hao Q; Kanda M; Tani Y
BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
15. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.
Furneri G; Santoni L; Ricella C; Prosperini L
BMC Health Serv Res; 2019 Jun; 19(1):436. PubMed ID: 31253138
[TBL] [Abstract][Full Text] [Related]
17. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Bigaut K; Fabacher T; Kremer L; Ongagna JC; Kwiatkowski A; Sellal F; Ferriby D; Courtois S; Vermersch P; Collongues N; Zéphir H; De Seze J; Outteryck O
Mult Scler; 2021 Apr; 27(5):729-741. PubMed ID: 32643521
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
[TBL] [Abstract][Full Text] [Related]
20. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]